How to predict severe influenza in hospitalized patients
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.
The four-year project took samples from patients hospitalised with influenza at up to five time points during their hospital stay, and 30 days after discharge. They analysed the… read more.
Roche has announced that the European Commission has approved Tecentriq (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have… read more.
Fasting diets have risen in popularity in recent years, however little is known about the long-term impact of these diets, particularly for future generations. New research, published today… read more.
Pfizer and BioNTech SE announced that the FDA has expanded the Emergency Use Authorization (EUA) for their Comirnaty COVID-19 vaccine to include individuals 12 to 15 years of… read more.
New research led by scientists from McMaster University and Charité — Universitätsmedizin Berlin in Germany has found it happens during and after birth, and not before. McMaster researchers… read more.
Merck Inc announced that the FDA has approved Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy, for the first-line treatment of patients… read more.
CMR Surgical (CMR) – a global surgical robotics business – announced the expanded use of its next-generation surgical robotic system Versius in Europe. For the first time, Versius… read more.
Merck Inc., hosted on 3 May an Organon management investor day meeting, to detail across women’s health, biosimilars and established brands.The new company will be launched on 3… read more.
GlaxoSmithKline plc announced the European Commission has approved the expanded use of intravenous and subcutaneous Benlysta (belimumab) in combination with background immunosuppressive therapies for the treatment of adult… read more.
Pfizer Canada ULC and BioNTech SE announced that Health Canada has expanded the Interim Order authorization for their COVID-19 vaccine to include individuals 12 to 15 years of… read more.
Horizon Therapeutics plc announced the publication of a new analysis of the pivotal Phase II/III N-MOmentum trial for Uplizna (inebilizumab-cdon), assessing the potential for reduced risk of worsening… read more.
Department of Health & Social Care (UK) Statement made on 7 May 2021:There have been reports of extremely rare adverse events of concurrent thrombosis (blood clots) and thrombocytopenia… read more.